What is the role of the Hybrid Capture II assay for HPV in workup for cervical cancer?

Updated: Feb 12, 2019
  • Author: Cecelia H Boardman, MD; Chief Editor: Warner K Huh, MD  more...
  • Print
Answer

The Hybrid Capture II assay for HPV was approved by the FDA in 2003 as a new approach for cervical cancer. This test is useful for interpreting equivocal results from a Pap test. If a woman has a Pap test result showing ASCUS but a subsequent HPV test is negative, she can be rescreened with Pap testing in 3 years; if the HPV test is positive, then additional workup with a colposcopy is indicated.

The ACS guidelines favor using HPV testing with cytology in women aged 30 years and older. If both tests are negative, then the next Pap test can be delayed for 5 years.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!